The trial, known as ADO2, will utilize OmniScience's recently developed product, Vivo, which uses generative AI to centralize and analyze clinical trial data in real time. Photo omniscience.bio

Houston data science firm OmniScience announced this month that it has partnered with Florida-based INmune Bio (NASDAQ: INMB) on a global Phase 2 Alzheimer’s disease clinical trial.

The trial, known as ADO2, will utilize OmniScience's recently developed product, Vivo, which uses generative AI to centralize and analyze clinical trial data in real time, according to a release. The two companies also partnered during Vivo’s development and recent roll-out.

"OmniScience and INmune Bio share a vision to transform how clinical trial teams engage with data – transforming data into knowledge in real time and informing decisions that increase the probability of success,” Angela Holmes, CEO of OmniScience, says in a statement. “As our partnership moves forward, we’re gaining further insights from the INmune team that we can integrate into Vivo’s roadmap. We look forward to our continued mutual success.”

The ADO2 trial will investigate INmune Bio's clinical-stage biotechnology XPro in patients with mild cognitive impairment or Alzheimer’s disease with brain inflammation, according to its website. Its products are focused on "restoring function in the body's innate immune system to fight disease."

The trial is overenrolled with 208 patients diagnosed with mild Alzheimer’s disease or mild cognitive impairment. The top-line results are expected to be released in Q2 2025.

"A global trial of this size is vast, and Vivo will be critical in our ability to analyze cognitive results,” Tara Lehner, INmune Bio’s vice president of clinical operations, says in the statement. “With genAI provided by Vivo, we can amplify our clinical teams’ capabilities, turning complex data into actionable insights at unprecedented speed, which means we can get answers—and treatments—to patients faster.”

INmune will be able to use OmniScience's Vivo product to unify data from electronic data capture, clinical trial management systems, patient-reported outcomes, clinical outcome assessments, labs, wearables, safety databases and more, according to the statement. The product has been shown to improve data quality and visualizations and reduce the reliance on spreadsheet-based data analysis during clinical trials.

Omniscience was originally founded in 2017, then known as Mercury Data Science. It rebranded and changed its name earlier this year. Holmes was named CEO in 2022.

Omniscience's Vivo product recently won first place in the CNS Summit 2024 Innovation Showcase in Boston and the Blue Whale Ribbon at the inaugural Whale Tank pitch competition during the 2024 Innovation Network Gathering (ING) in West Chester, Pennsylvania.

DocJuris has raised a $8 million series A. Photo via Getty Images

Houston legal tech platform raises $8M series A, plans to hire

fresh funding

Houston-based DocJuris, a leader in AI contract review, announced the successful closure of its series A funding round by raising $8 million in new capital. This brings the total capital raised to date to $11.2 million.

"DocJuris AI has become an industry-leading platform that empowers enterprise legal, procurement, and sales teams to close deals faster while reducing risk," DocJuris CEO and Founder Henal Patel says in a news release. "With this funding, we will continue scaffolding our platform around generative AI, expand our customer success team, and grow our user base."

The most active venture capital firm in Texas Silverton Partners led the round with participation from previous investors Watertower Ventures, Surface Ventures, and Seed Round Capital.

Companies like Siemens, Dell, FedEx, Toyota, and Duke Energy already use DocJuris with its AI-powered contract negotiation software that automates imporrant tasks during the review, redlining, and negotiation of contracts. DocJuris uses a platform to screen third-party contracts in seconds, can redline clauses with playbook-compliant edits in one click, and also generate formatted track changes, exception tables, and amendments with a cloud-based application.

The Association of Corporate Counsel, awarded DocJuris the Value Champion Award in 2023 due to the reduced contract cycle times to minutes with AI.

“We wanted to replace repetitive, manual tasks and free up valuable time for our employees to focus on more impactful work,” lead attorney for Flex's Global Procurement and Supply Chain Iringo Csifo-Nagy adds. “To achieve this, we developed a turnkey solution for AI-driven contract reviews together with the DocJuris team."

In its first round of funding in 2021, DocJuris raised $3.2 million in seed capital.

In partnership with a digital consultant company, the Mark Cuban Foundation is looking for high school students interested in AI. Photo via Getty Images

New AI program powered by Mark Cuban opens applications for Houston students

eyes on ai

The Mark Cuban Foundation is partnering with digital consultant company Perficient’s Houston office to bring a one-of-its-kind, free artificial intelligence camp to high school students in Houston.

Applications, which are open now online, will close September 30.

“With the proliferation of AI, it’s more important than ever to increase AI education – especially among today’s youth,” Bill Davis, senior vice president at Perficient, says in a news release.

The curriculum will focus on the latest developments in the world of AI and Generative AI. The camp — held at Perficient’s Houston office on November 2, 9 and 16 — will provide students with necessary tools and technologies to help inspire a new generation of AI users and professionals. The camp aims to help underserved high school students with a focus on recruiting students of color, first generation college students, girls, and those from lower to moderate income households.

“As AI continues to become an undeniable force in all of our lives, it’s crucial that we open the door to this knowledge, especially to young people who want to explore it,” Cuban says in the release. “While technology expands and becomes more advanced, it becomes more critical that we ensure our students are prepared when they apply for schools or jobs in the future. Thanks to our work with Perficient, the bootcamp will offer an avenue to explore this fascinating field of technology to any student, no matter their means.”

Students can select from six tracks in the course that include healthcare, arts and entertainment, business and entrepreneurship, computer science, sports science, or education and career readiness. The AI Bootcamps are introductory and accessible to students in ninth through 12th grade with an interest in technology without any prior computer science experience. Transportation, resources and food will be provided.

As classes like STEM increase in popularity more programs have been created to help increase interest. More than 233,000 high school students in Texas took Career and Technical Education courses focused on STEM from 2020-2021.

“We’re proud to partner with the Mark Cuban Foundation to educate the next generation of technology leaders, mentoring students in AI, and ensuring the future of STEM,” Davis said in a news release.

BrainLM is now well-trained enough to use to fine-tune a specific task and to ask questions in other studies. Photo via Getty Images

Houston researchers create AI model to tap into how brain activity relates to illness

brainiac

Houston researchers are part of a team that has created an AI model intended to understand how brain activity relates to behavior and illness.

Scientists from Baylor College of Medicine worked with peers from Yale University, University of Southern California and Idaho State University to make Brain Language Model, or BrainLM. Their research was published as a conference paper at ICLR 2024, a meeting of some of deep learning’s greatest minds.

“For a long time we’ve known that brain activity is related to a person’s behavior and to a lot of illnesses like seizures or Parkinson’s,” Dr. Chadi Abdallah, associate professor in the Menninger Department of Psychiatry and Behavioral Sciences at Baylor and co-corresponding author of the paper, says in a press release. “Functional brain imaging or functional MRIs allow us to look at brain activity throughout the brain, but we previously couldn’t fully capture the dynamic of these activities in time and space using traditional data analytical tools.

"More recently, people started using machine learning to capture the brain complexity and how it relates it to specific illnesses, but that turned out to require enrolling and fully examining thousands of patients with a particular behavior or illness, a very expensive process,” Abdallah continues.

Using 80,000 brain scans, the team was able to train their model to figure out how brain activities related to one another. Over time, this created the BrainLM brain activity foundational model. BrainLM is now well-trained enough to use to fine-tune a specific task and to ask questions in other studies.

Abdallah said that using BrainLM will cut costs significantly for scientists developing treatments for brain disorders. In clinical trials, it can cost “hundreds of millions of dollars,” he said, to enroll numerous patients and treat them over a significant time period. By using BrainLM, researchers can enroll half the subjects because the AI can select the individuals most likely to benefit.

The team found that BrainLM performed successfully in many different samples. That included predicting depression, anxiety and PTSD severity better than other machine learning tools that do not use generative AI.

“We found that BrainLM is performing very well. It is predicting brain activity in a new sample that was hidden from it during the training as well as doing well with data from new scanners and new population,” Abdallah says. “These impressive results were achieved with scans from 40,000 subjects. We are now working on considerably increasing the training dataset. The stronger the model we can build, the more we can do to assist with patient care, such as developing new treatment for mental illnesses or guiding neurosurgery for seizures or DBS.”

For those suffering from neurological and mental health disorders, BrainLM could be a key to unlocking treatments that will make a life-changing difference.

Researchers at Baylor College of Medicine’s Human Genome Sequencing Center have trained an AI assistant to explain genetic test results to patients. Photo via Getty Images

Houston researches tap into GenAI for communicating genetic test results

hi, tech

Artificial intelligence in the health care setting has a lot of potential, and one Houston institution is looking into one particular use.

Researchers at Baylor College of Medicine’s Human Genome Sequencing Center have trained an AI assistant to explain genetic test results to patients. According to findings published in the Journal of the American Medical Informatics Association (JAMIA), the team has developed generative AI to understand and interpret genetic tests. They have also tested its accuracy against Open AI’s ChatGPT 3.5.

“We created a chatbot that can provide guidance on general pharmacogenomic testing, dosage implications, and the side effects of therapeutics, and address patient concerns,” explains first author Mullai Murugan in a press release. Murugan is director of software engineering and programming at the Human Genome Sequencing Center. “We see this tool as a superpowered assistant that can increase accessibility and help both physicians and patients answer questions about genetic test results.”

The initial chatbot training specifically targeted pharmacogenomic testing for statins, meaning a patient’s potential response to cholesterol-lowering drugs, as dictated by genetics.

Murugan explains why they decided to create their own chatbot in the key publication on statin pharmacogenomics was published in May 2022, four months after the training cutoff date for ChatGPT 3.5 in January 2022. Alternatively, her team’s technology uses Retrieval Augmented Generation (RAG) and was trained on the most recent guidelines.

How did the two AI assistants compare? Four experts on cardiology and pharmacogenomics rated both chatbots based on accuracy, relevancy, risk management, and language clarity, among other factors. Though the AI scored similarly on language clarity, Baylor’s chatbot scored 85 percent in accuracy and 81 percent in relevancy compared to ChatGPT’s 58 percent in accuracy and 62 percent in relevancy when asked questions from healthcare providers.

“We are working to fine-tune the chatbot to better respond to certain questions, and we want to get feedback from real patients,” Murugan says. “Based on this study, it is very clear that there is a lot of potential here.” Nonetheless, Murugan emphasized that there is much work still to be done before the program is ready for clinical applications. That includes training the chatbot to explain results in the language used by genetic counselors. Funds from the NIH’s All of Us Research Program helped to make the research possible.

There are three topics in particular that business owners should refresh and/or make sure they include in their HR policies and employee handbook. Photo via Getty Images

3 things Houston companies need to freshen up when it comes to their HR practices

guest column

Just as we typically look to freshen up our homes this time of year, the same needs to be done for employee handbooks. Employee handbooks streamline HR operations, mitigate risks and set expectations to protect a business from negative workplace behavior by outlining employee policies and procedures.

There are three topics in particular that business owners should refresh and/or make sure they include in their HR policies and employee handbook: in-office attendance, social media and artificial intelligence (AI).

In-office attendance

When taking a closer look at hybrid workplace policies, the in-office attendance policies should align with your organizational goals. Whether you decide to implement hybrid work permanently or eventually return to being in the office completely, the return-to-office (RTO) policies should reflect those goals.

Clear expectations are especially important when defining office attendance rules. When attendance policies are set, employees respond best when they are fair, accessible and easily understood. Detailed policies outlining the nuances and consequences can help reduce noncompliance while supporting accountability.

Policies need consistent enforcement for them to be effective. Hybrid policies set prior to or during the pandemic may now be loosely enforced. The policies may state for employees to be in the office three days a week, but there may be no accountability for not meeting the mandate. Not enforcing attendance policies can give the impression that it is okay to violate other policies, too. Reviewing your policies allows you to course correct and write a policy reflecting your corporate culture and goals. You’ll then be able to reintroduce the attendance policy and enforce it across the board as intended.

Social media

You are hard pressed to find an employee without a social media account, whether it is TikTok or LinkedIn. If your business does not have a social media policy with guidelines surrounding employees’ online behaviors, now is the time to put one in place. If you do have a policy, social media changes quickly enough to warrant an annual review.

Social media policies should set boundaries between personal and professional use of social media. Employee activity on social media outside of work can influence business, as employees are often seen as reflecting the company. It is also important to note that social media policies should be based on input from senior management, HR, legal and IT, not just marketing.

The social media policy should delineate between an employee’s personal and professional use, establish a code of conduct and outline its use as part of crisis communications. Social media can just as easily elevate your brand, and you can potentially ask employees to share positive work experiences online.

Cybersecurity should also be addressed in social media policies. As it has become more common for hackers to infiltrate personal emails and social media accounts, policies can prohibit employees from storing company documents in their personal social media and email accounts for security purposes.

Artificial Intelligence (AI)

AI seems to be changing the way we do business daily. However, the policies surrounding company use of AI are lacking at many organizations. Research from McKinsey states only one in five employers have established policies governing their employees use of AI.

AI technology has already streamlined many business practices, but it can also present major risks. Inaccuracy can threaten your business if employees use generative AI for assistance in completing writing tasks, for instance, and the system may not generate accurate or original information.

As we learn the evolving and complex nuances of AI, creating a policy needs careful attention. You may consider developing an AI team to write a comprehensive, well-researched AI policy tailored to your organization. This working group should gather insights from leaders within the organization, including frontline managers, to fully understand how employees use, or might use, AI. This team should be charged with considering the ethical aspects of AI’s use and ensuring the policy aligns with company values.

One of the most critical elements of the policy is an accountability process or system. The policy should clearly outline any corrective action or disciplinary steps associated with using AI in a manner that harms the business and/or its clients. Just as important, the policy should outline how to use and how to avoid misusing AI. Since AI continues to evolve month to month, this is a policy that will require more attention and revisioning throughout the year.

Keeping a critical eye on HR policies is an important part of business success. Setting aside time to review, update and even create new policies now – before being faced with an issue – can potentially mitigate costly challenges down the road.

------

Karen Leal is performance specialist with Houston-based Insperity, a provider of human resources offering a suite of scalable HR solutions available in the marketplace.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

5 Houston scientists named winners of prestigious Hill Prizes 2026

prized research

Five Houston scientists were recognized for their "high-risk, high-reward ideas and innovations" by Lyda Hill Philanthropies and the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

The 2026 Hill Prizes provide seed funding to top Texas researchers. This year's prizes were given out in seven categories, including biological sciences, engineering, medicine, physical sciences, public health and technology, and the new artificial intelligence award.

Each recipient’s institution or organization will receive $500,000 in direct funding from Dallas-based Lyda Hill Philanthropies. The organization has also committed to giving at least $1 million in discretionary research funding on an ad hoc basis for highly-ranked applicants who were not selected as recipients.

“It is with great pride that I congratulate this year’s Hill Prizes recipients. Their pioneering spirit and unwavering dedication to innovation are addressing some of the most pressing challenges of our time – from climate resilience and energy sustainability to medical breakthroughs and the future of artificial intelligence,” Lyda Hill, founder of Lyda Hill Philanthropies, said in a news release.

The 2026 Houston-area recipients include:

Biological Sciences: Susan M. Rosenberg, Baylor College of Medicine

Rosenberg and her team are developing ways to fight antibiotic resistance. The team will use the funding to screen a 14,000-compound drug library to identify additional candidates, study their mechanisms and test their ability to boost antibiotic effectiveness in animal models. The goal is to move toward clinical trials, beginning with veterans suffering from recurrent infections.

Medicine: Dr. Raghu Kalluri, The University of Texas MD Anderson Cancer Center

Kalluri is developing eye drops to treat age-related macular degeneration (AMD), the leading cause of vision loss globally. Kalluri will use the funding to accelerate studies and support testing for additional ocular conditions. He was also named to the National Academy of Inventors’ newest class of fellows last month.

Engineering: Naomi J. Halas, Rice University

Co-recipeints: Peter J. A. Nordlander and Hossein Robatjazi, Rice University

Halas and her team are working to advance light-driven technologies for sustainable ammonia synthesis. The team says it will use the funding to improve light-driven catalysts for converting nitrogen into ammonia, refine prototype reactors for practical deployment and partner with industry collaborators to advance larger-scale applications. Halas and Nordlander are co-founders of Syzygy Plasmonics, and Robatjazi serves as vice president of research for the company.

The other Texas-based recipients include:

  • Artificial Intelligence: Kristen Grauman, The University of Texas at Austin
  • Physical Sciences: Karen L. Wooley, Texas A&M University; Co-Recipient: Matthew Stone, Teysha Technologies
  • Public Health: Dr. Elizabeth C. Matsui, The University of Texas at Austin and Baylor College of Medicine
  • Technology: Kurt W. Swogger, Molecular Rebar Design LLC; Co-recipients: Clive Bosnyak, Molecular Rebar Design, and August Krupp, MR Rubber Business and Molecular Rebar Design LLC

Recipients will be recognized Feb. 2 during the TAMEST 2026 Annual Conference in San Antonio. They were determined by a committee of TAMEST members and endorsed by a committee of Texas Nobel and Breakthrough Prize Laureates and approved by the TAMEST Board of Directors.

“On behalf of TAMEST, we are honored to celebrate the 2026 Hill Prizes recipients. These outstanding innovators exemplify the excellence and ambition of Texas science and research,” Ganesh Thakur, TAMEST president and a distinguished professor at the University of Houston, added in the release. “Thanks to the visionary support of Lyda Hill Philanthropies, the Hill Prizes not only recognize transformative work but provide the resources to move bold ideas from the lab to life-changing solutions. We are proud to support their journeys and spotlight Texas as a global hub for scientific leadership.”

Investment bank opens new Houston office focused on energy sector

Investment bank Cohen & Co. Capital Markets has opened a Houston office to serve as the hub of its energy advisory business and has tapped investment banking veteran Rahul Jasuja as the office’s leader.

Jasuja joined Cohen & Co. Capital Markets, a subsidiary of financial services company Cohen & Co., as managing director, and head of energy and energy transition investment banking. Cohen’s capital markets arm closed $44 billion worth of deals last year.

Jasuja previously worked at energy-focused Houston investment bank Mast Capital Advisors, where he was managing director of investment banking. Before Mast Capital, Jasuja was director of energy investment banking in the Houston office of Wells Fargo Securities.

“Meeting rising [energy] demand will require disciplined capital allocation across traditional energy, sustainable fuels, and firm, dispatchable solutions such as nuclear and geothermal,” Jasuja said in a news release. “Houston remains the center of gravity where capital, operating expertise, and execution come together to make that transition investable.”

The Houston office will focus on four energy verticals:

  • Energy systems such as nuclear and geothermal
  • Energy supply chains
  • Energy-transition fuel and technology
  • Traditional energy
“We are making a committed investment in Houston because we believe the infrastructure powering AI, defense, and energy transition — from nuclear to rare-earth technology — represents the next secular cycle of value creation,” Jerry Serowik, head of Cohen & Co. Capital Markets, added in the release.

---

This article originally appeared on EnergyCaptialHTX.com.

MD Anderson makes AI partnership to advance precision oncology

AI Oncology

Few experts will disagree that data-driven medicine is one of the most certain ways forward for our health. However, actually adopting it comes at a steep curve. But what if using the technology were democratized?

This is the question that SOPHiA GENETICS has been seeking to answer since 2011 with its universal AI platform, SOPHiA DDM. The cloud-native system analyzes and interprets complex health care data across technologies and institutions, allowing hospitals and clinicians to gain clinically actionable insights faster and at scale.

The University of Texas MD Anderson Cancer Center has just announced its official collaboration with SOPHiA GENETICS to accelerate breakthroughs in precision oncology. Together, they are developing a novel sequencing oncology test, as well as creating several programs targeted at the research and development of additional technology.

That technology will allow the hospital to develop new ways to chart the growth and changes of tumors in real time, pick the best clinical trials and medications for patients and make genomic testing more reliable. Shashikant Kulkarni, deputy division head for Molecular Pathology, and Dr. J. Bryan, assistant professor, will lead the collaboration on MD Anderson’s end.

“Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information,” Dr. Donna Hansel, division head of Pathology and Laboratory Medicine at MD Anderson, said in a press release. “This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”

SOPHiA GENETICS is based in Switzerland and France, and has its U.S. offices in Boston.

“This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research,” Dr. Philippe Menu, chief product officer and chief medical officer at SOPHiA GENETICS, added in the release. “With SOPHiA DDM as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”